Chinese pharma price-fixing decision results in first individual penalty
A subsidiary of Hong Kong-listed Shanghai Pharmaceuticals and one of its business executives were fined by Shanghai's market regulator for colluding with two rivals in price-fixing and market division agreements. This...To view the full article, register now.
Already a subscriber? Click here to view full article